Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: RECEPTOR ; CANCER ; EXPRESSION ; tumor ; carcinoma ; Germany ; human ; HYBRIDIZATION ; PROTEIN ; PROTEINS ; TISSUE ; TUMORS ; PATIENT ; FAMILY ; MARKER ; hormone ; IN-SITU ; PROGRESSION ; immunohistochemistry ; PATTERNS ; prostate cancer ; PROSTATE-CANCER ; MARKERS ; BENIGN ; GLYCATION END-PRODUCTS ; RAGE ; CARCINOMAS ; adenocarcinoma ; intraepithelial neoplasia ; NEURITE OUTGROWTH ; KAPPA-B ; CANCER PATIENTS ; HEALTHY ; prostate carcinoma ; OXIDANT STRESS ; SERUM ; in situ hybridization ; ELISA ; RE ; END ; TUMORIGENESIS ; HUMAN PROSTATE ; HYPERPLASIA ; TUMOR TISSUE ; MOLECULAR-GENETICS ; HUMAN-PROSTATE ; S100 PROTEINS ; EXPRESSION PATTERNS ; SERUM-LEVELS ; TUMOR DIFFERENTIATION
    Abstract: Purpose: S100 proteins comprise a family of calcium-modulated proteins that have recently been associated with epithelial tumors. We examined the expression of two members of this family, S10OA8 and S100A9, together with the S100 receptor RAGE (receptor for advanced glycation end products) in human prostate adenocarcinomas and in prostatic intraepithelial neoplasia. Experimental Design:Tissue specimens of 75 patients with organ-confined prostate cancer of different grades were analyzed by immunohistochemistry for expression of S10OA8, S100A9, and RAGE. In addition, in situ hybridization of S10OA8 and S10OA9 was done for 20 cases. An ELISA was applied to determine serum concentrations of S10OA9 in cancer patients compared with healthy controls or to patients with benign prostatic hyperplasia (BPH). Results: S100A8, S100A9, and RAGE were up-regulated in prostatic intraepithelial neoplasia and preferentially in high-grade adenocarcinomas, whereas benign tissue was negative or showed weak expression of the proteins. There was a high degree of overlap of S10OA8 and S10OA9 expression patterns and of S100A8 or S100A9 and RAGE, respectively. Frequently, a gradient within the tumor tissue with an increased expression toward the invaded stroma of the prostate was observed. S100A9 serum levels were significantly elevated in cancer patients compared with BPH patients or healthy individuals. Conclusion: Our data suggest that enhanced expression of S100A8, S100A9, and RAGE is an early event in prostate tumorigenesis and may contribute to development and progression or extension of prostate carcinomas. Furthermore, S100A9 in serum may serve as useful marker to discriminate between prostate cancer and BPH
    Type of Publication: Journal article published
    PubMed ID: 16033829
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: CANCER ; CELLS ; EXPRESSION ; tumor ; carcinoma ; Germany ; RISK ; SURGERY ; PATIENT ; ANTIGEN ; treatment ; PROGRESSION ; MALIGNANCIES ; PROSTATE-CANCER ; BENIGN ; PREDICTION ; SERUM ; IGF-I ; ELISA ; MALIGNANCY ; INCREASE ; GROWTH-FACTOR-I ; LEVEL ; SERUM-LEVELS ; biological markers ; prostatic hyperplasia ; FACTOR-BINDING PROTEIN-2 ; insulin-like Growth factor II ; prostate-specific antigen ; prostatic neoplasms
    Abstract: Purpose: IGF-I serum levels have been demonstrated as being associated with prostate cancer (PCa) and can serve as a predictive factor for the risk of PCa development. However, the role of IGF-II in PCa and its importance as a predictive marker is still unclear. Our aim was to determine PSA and IGF-II serum levels in patients with PCa and benign prostatic hyperplasia (BPH) and to analyse the value of IGF-II as an additional predictive factor in the diagnostics of Ka. Methods: 112 patients who underwent surgery for BPH or PCa (no hormonal treatment, no further malignancies) were included in this study ((I) 38 PCa, PSA 〈= 15 ng/ml; (II 34 PCa, PSA 〉 5 ng/ml; (III) 40 BPH). Preoperative serum levels of total PSA and total IGF-II were determined by ELFA and ELISA, respectively. Results: PSA levels were (1) 5.7 +/- 1.9 ng/ml; (11) 25.0 +/- 11.5 ng/ml and (III) 4.0 +/- 2.8 ng/ml. (II) was statistically associated with a high grading (2b/3; p = 0.0182), a high Gleason sum score (7-10; p = 0.0049) and a non-organ confined tumor (T3/4; p = 0.0009) compared to (I), all Chi(2) test. IGF-II levels were significantly higher in PCa (I+II) compared to BPH (833.8 +/- 238.9 ng/ml vs. 633.3 +/- 141.4 ng/ml, p 〈 0.0001, t-test). Both PSA and IGF-II were associated with tumor staging (p = 0.0097, p = 0.0308; t-test). No significant correlation was observed between PSA and IGF-II levels. Logistic regression analysis revealed that the combination of PSA and IGF-II improves the prediction of tumor staging in PCa (p = 0.0175 and p = 0.0459, Wald test). Additionally, the combination of PSA and IGF-II can significantly increase discrimination between BPH and PCa; each p 〈 0.0001, Wald test. Conclusions: This study provides evidence that IGF-II serum levels may serve as an additional parameter for (a) improved determination of tumor staging and (b) better discrimination between BPH and PCa. (c) 2005 Elsevier B.V. All rights reserved
    Type of Publication: Journal article published
    PubMed ID: 16386354
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Abstract: The plakophilins, members of the armadillo-repeat family, consist of three different proteins (PKP1-3) that are specifically recruited to desmosomal plaques in a highly cell type-specific manner. Using immunofluorescence, immunoelectron microscopy, and immunoblot, we found that all three plakophilins occurred in luminal and basal cells of the pseudostratified prostate epithelium. The analysis of 135 cases of prostatic adenocarcinomas grouped into tumors with low (Gleason score 〈 or = 6), intermediate (Gleason score 7), and high Gleason score (8 〈 or = Gleason score 〈 or = 10) showed that the expression of PKP1 was reduced or lost in adenocarcinomas with high Gleason scores. The expression of PKP2 was unchanged in all prostatic adenocarcinomas analyzed. In contrast, PKP3 expression was increased in carcinomas with high Gleason scores in comparison with carcinomas with low Gleason scores. In DU 145 cell lines with either overexpression or knockdown of PKP3, both imbalances resulted in fewer desmosomal cell contacts. In addition, overexpression of PKP3 in DU 145 cells led to an augmentation in proliferation rate. Our data imply that both loss of PKP1 and up-regulation of PKP3 expression are biologically important events in prostate cancer and are associated with a more aggressive phenotype.
    Type of Publication: Journal article published
    PubMed ID: 20348237
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Keywords: ANGIOGENESIS ; CANCER ; tumor ; carcinoma ; Germany ; MODEL ; PROSTATE ; NEW-YORK ; DIFFERENTIATION ; TISSUE ; TUMORS ; TIME ; PATIENT ; MR ; MRI ; SEQUENCE ; SEQUENCES ; SIGNAL ; DIFFERENCE ; EXCHANGE ; PARAMETERS ; CERVICAL-CARCINOMA ; MORPHOLOGY ; CARCINOMAS ; INVOLVEMENT ; GD-DTPA ; prostate carcinoma ; prostate,dynamic MRI,micro vessel density
    Abstract: Aim. The suitability of dynamic parameters of the two-compartment model for detecting prostate carcinomas and its correlation with tumor microvascular density were evaluated.Methods. The study included 43 patients with biopsy-proven prostate carcinoma: 28 were examined by 1.0-T MRI (Turbo-FLASH) and 15 by 1.5-T MRI (FLASH) with infusion of 0.1 mmol/kg Gd-DTPA. Signal time curves were parametrized with an open two-compartment model in amplitude and exchange rate constants (k(ep)). The microvascular density of resected prostate carcinomas was determined.Results. The microvascular density in the tumors was significantly higher than in the adjacent healthy prostate tissue and correlated in both sequences with k(ep). Prostate carcinomas of the peripheral zone were demarcated by amplitude and k(ep). In the Turbo-FLASH sequence there was a significant difference between the tumor tissue and healthy peripheral zone in terms of k(ep) and in the FLASH sequence in terms of amplitude.Conclusion. Prostate carcinomas can be visualized with dynamic T1-weighted MR sequences using a two-compartment model. Moreover, the parameter k(ep) reveals the microvascular density in the tumor and can thus provide valuable clinical information for characterizing the tumors
    Type of Publication: Journal article published
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    Keywords: CANCER ; tumor ; carcinoma ; evaluation ; Germany ; MICROVESSEL DENSITY ; MODEL ; MODELS ; PROSTATE ; DENSITY ; SAMPLE ; DIFFERENTIATION ; TISSUE ; TUMORS ; ACCURACY ; TIME ; PATIENT ; CONTRAST ; INJECTION ; MRI ; SIGNAL ; BREAST ; score ; prostate cancer ; PROSTATE-CANCER ; REGION ; REGIONS ; EXCHANGE ; PARAMETERS ; BENIGN ; CARCINOMAS ; CURVES ; sensitivity ; contrast media ; dynamic MRI ; F ; CONTRAST ENHANCEMENT ; RADICAL PROSTATECTOMY ; dynamic contrast enhanced MRI ; ENHANCED MRI ; ENHANCEMENT ; intensity ; OCT ; pharmacokinetic model ; prostate neoplasms
    Abstract: Evaluation of the accuracy of descriptive and physiological parameters calculated from signal intensity-time curves using T1-weighted dynamic contrast enhanced MRI (DCE MRI) to differentiate prostate cancers from the peripheral gland. Twenty-seven patients with prostate cancers were examined with DCE MRI prior radical prostatectomy. Regions of interest were defined in tumors and non-affected areas in the peripheral zone. Dynamic data were parameterized in amplitude and exchange rate constant (k(ep)) using a two-compartment model. Additionally, relative slope during 26, 39, 52 and 65 s, areas under the curve (AUC) and time to start of signal intensity increase (t(lag)) were determined. Vessel density (VD) of excised prostates was quantified in tumor areas using a CD34 stain. The parameter slope(52) showed 20 % higher values (P 〈 0.001) in tumors than in the peripheral gland and compared with the other parameters the largest area under the ROC curve (0.81). The minimum total error rate was attained at a cut-point of 0.021, yielding a sample value of sensitivity and specificity of 70 % and 88 %, respectively, and a bias-corrected sum of sensitivity and specificity of 1.54. In addition, amplitude (P 〈 0.001), k(ep) (P = 0.03) and AUC (P 〈 0.001) were significantly higher in tumors. t(lag) did not discriminate carcinomas from glandular tissue. VD was higher in tumors than in the non-affected peripheral prostate (P = 0.05). However, none of the dynamic parameters in carcinomas showed a significant correlation with VD or Gleason score. Although pharmaco-kinetic modeling in DCE MRI showed potential to discriminate prostate cancers from peripheral prostate tissue, descriptive parameters of the early signal enhancement after contrast media injection reached higher sensitivity and specificity
    Type of Publication: Journal article published
    PubMed ID: 15232714
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    Keywords: RECEPTOR ; CANCER ; CELLS ; EXPRESSION ; GROWTH ; GROWTH-FACTOR ; tumor ; FACTOR RECEPTOR ; Germany ; human ; PATHWAY ; PROSTATE ; SYSTEM ; RISK ; PROTEIN ; PROTEINS ; COMPONENTS ; TISSUE ; TUMORS ; PATIENT ; LIGAND ; MARKER ; ANTIGEN ; BINDING ; hormone ; PROGRESSION ; immunohistochemistry ; UP-REGULATION ; prostate cancer ; PROSTATE-CANCER ; PARAMETERS ; LIGANDS ; BENIGN ; PHENOTYPE ; adenocarcinoma ; ADENOCARCINOMAS ; intraepithelial neoplasia ; PREDICTORS ; BEHAVIOR ; FACTOR-I ; protein expression ; P27(KIP1) ; insulin ; SERUM ; IGF-I ; RE ; FRACTION ; intensity ; development ; BINDING PROTEIN-3 ; RECEPTOR SUBSTRATE-1 ; LEVEL ; insulin-like growth factor ; SERUM-LEVELS ; TUMOR BEHAVIOR ; HIGH-GRADE ; IGF-BINDING PROTEIN-3 ; insulinlike growth factor system
    Abstract: There is an evidence that components of the insulin-like growth factor (IGF)-signaling pathway are involved in the development and progression of prostate cancer. The aim of the present study was to provide a comprehensive analysis of the expression levels of proteins of the IGF axis in prostate cancer. We studied expression of the ligands IGF-I and IGF-II, the inhibitory IGF binding protein-3, the type I IGF receptor (IGF-IR), and the downstream mediator insulin receptor substrate-1 by immunohistochemistry in 56 tissue specimens (28 low-grade and 28 high-grade prostate adenocarcinomas). Protein expression in tumor areas, prostatic intraepithelial neoplasias (PINs), and adjacent benign prostatic tissue were evaluated regarding staining intensity and fraction of positive cells. An immunoreactivity score was established from staining intensity and fraction of positive cells, and correlated with the prognostic clinicopathologic parameters prostate-specific antigen serum levels, Gleason score, and TNM stage. The expression levels of all proteins investigated, except IGF binding protein-3, were up-regulated in PIN and in cancer. IGF-I and IGF-II expression showed a higher expression in high-grade compared with low-grade tumor areas. IGF-I and IGF-II and insulin receptor substrate-1 immunoreactivity was higher in tumors from patients with preoperative prostate-specific antigen serum levels 10 ng/mL or greater, and IGF-II expression was correlated with Gleason score. The data indicate significant alterations in the IGF system as prostate cancer develops. Differential expression of growth-stimulating components of the IGF system may be associated with the malignant phenotype and more aggressive tumor behavior. Expression of IGFs, especially IGF-II, may be predictors of the outcome of prostate cancer. (c) 2005 Elsevier Inc. All rights reserved
    Type of Publication: Journal article published
    PubMed ID: 16260272
    Signatur Availability
    BibTip Others were also interested in ...
  • 7
    Keywords: CELL BIOLOGY ; adenocarcinoma ; BIOLOGY ; PROGRESSION ; TUMOR PROGRESSION ; tumor ; CELL ; Germany ; PROSTATE
    Type of Publication: Meeting abstract published
    Signatur Availability
    BibTip Others were also interested in ...
  • 8
  • 9
    facet.materialart.
    facet.materialart.
    German Medical Science; Düsseldorf, Köln
    In:  27. Deutscher Krebskongress; 20060322-20060326; Berlin; DOCPO303 /20060320/
    Publication Date: 2006-04-21
    Keywords: ddc: 610
    Language: English
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 10
    Keywords: APOPTOSIS ; CANCER ; CELLS ; EXPRESSION ; INVASION ; proliferation ; SURVIVAL ; tumor ; carcinoma ; CELL ; CELL-PROLIFERATION ; Germany ; human ; INHIBITION ; PATHWAY ; NEW-YORK ; TISSUE ; TUMORS ; ACTIVATION ; SERA ; primary ; ANTIGEN ; SIGNAL ; STIMULATION ; score ; hormone ; NEOPLASIA ; PROGRESSION ; immunohistochemistry ; TUMOR PROGRESSION ; PROSTATE-CANCER ; PRODUCT ; PARAMETERS ; BENIGN ; CARCINOMAS ; ADENOCARCINOMAS ; intraepithelial neoplasia ; OVEREXPRESSION ; SERUM LEVELS ; SECTIONS ; AKT ; AKT/protein kinase B,prostate,adenocarcinoma,tumor grade,immunohistochemistry ; P27(KIP1)
    Abstract: AKT/PKB is a central signaling molecule related to stimulation of cell proliferation and inhibition of apoptosis. Perturbations of AKT expression and function play an important role in tumor development and progression. We wanted to determine (a) whether AKT is overexpressed in human prostatic tumors, (b) whether AKT expression is correlated with tumor grade, and (c) whether AKT expression correlates with clinicopathological parameters. AKT expression was investigated by immunohistochemistry in sections from S6 paraffin-embedded prostate specimens displaying benign prostatic tissue (BPT), prostatic intraepithelial neoplasia (PIN), and primary tumors graded 2-5 according to Gleason. The staining intensity for AKT was significantly more pronounced in tumors compared to BPT, with PIN ranging between BPT and carcinomas. Similarly, the fraction of AKT-positive cells was higher in tumors than in BPT. A score of AKT expression (calculated as product from intensity and fraction of positive cells) ranging from 0-6 was also significantly higher in tumors than in BPT. Furthermore, the intensity of AKT expression in tumors showed a positive correlation with high preoperative serum levels of prostate specific antigen (PSA greater than or equal to 10 ng/ml, p = 0.0325). These data show that AKT is upregulated in prostate cancer and that expression is correlated with tumor progression. (C) 2003 Wiley-Liss, Inc
    Type of Publication: Journal article published
    PubMed ID: 14520710
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...